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ABSTRACT
We investigated the synthesis and biological effects of platelet-activat
ing factor (PAF) in the human endometrial cancer cell line HEC-1A. We
found that HEC-1A cells actively synthesize and release PAF, as demon
strated by both [3H]acetate incorporation into PAF and gas chromatog-
raphy-mass spectrometry studies. HEC-1A cells not only synthesize but
also respond to PAF. Indeed, in fura-2-loaded cells, PAF stimulates
[Ca2+]| increase with a median effective concentration of 5.6 nM. Further
more, PAF induces a time-dependent expression increase of the nuclear
protooncogene c-fos with a median effective concentration of 130 nM and
stimulates DNA synthesis (median effective concentration, 700 nM). All of
these effects are inhibited by the PAF receptor antagonist L659,989.
Radioligand binding studies indicated the presence of two populations of
PAF receptors with affinity constants in the nanomolar and micromolar
range. Since the PAF antagonist per se inhibits DNA synthesis and cell
proliferation, we suggest that PAF supports an autocrine growth circuit in
HEC-1A cells. On the contrary, in the uterine leiomyosarcoma cell line
SK-UT-1, which does not express specific binding sites for PAF, neither
this phospholipid nor its receptor antagonist affect DNA synthesis. Our
results provide evidence for the existence of an autocrine proliferative
loop involving PAF in the endometrial cancer cell line HEC-1A.
INTRODUCTION
PAF3 is a potent, proinflammatory, ubiquitous lipid mediator (1, 2),
chemically defined as l-alkyl-Z-acetyl-s/i-glycero-S-phosphorylcho-
line. Several lines of evidence suggest that PAF plays a significant
paracrine role in stromal-epithelial cell interactions in the uterus,
particularly during the implantation process (3). Indeed, although PAF
synthesis is usually initiated in response to a variety of stimuli (2), a
significant amount of this phospholipid has been found in rat uterus in
the absence of any stimulation (4). In addition, human endometrial
cells in primary culture synthesize PAF, both in basal conditions and
following stimulation with progesterone (5, 6), whereas specific PAF
binding sites are present in rabbit endometrium peaking during the
periimplantation period (7-9).
Although an effect of PAF on cell proliferation has not been
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precisely defined, recent data indicate that this phospholipid stimu
lates various intracellular signaling pathways linked to cellular pro
liferation, such as tyrosine phosphorylation (10-12) and mRNA tran
scription for the c-fos and c-jun oncogenes (12-16). In addition, ether
lipids with structural similarity to PAF (17) and some PAF receptor
antagonists (18, 19) are potent antiproliferative agents in several
cancer cell lines.
The aim of the present study was to investigate production and
biological activity of PAF in HEC-1A cells. We now report evidence
for a PAF-driven autocrine loop critically involved in the regulation of
proliferation of this endometrial cancer cell line.
MATERIALS AND METHODS
Chemicals. PAF, lyso-PAF, C-PAF, Fura 2/AM, A23187, ionomycin,
BAPTA/AM, and propidium iodide were obtained from Calhiochem (La Jolla,
CA). The sodium salt of [3H]acetic acid ( 1.9 Ci/mmol), [3H]acetyl-CoA (4
Ci/mmol), [mi>;/iY/-3H]thymidine (2 Ci/mmol), and |'H]PAF (60 Ci/mmol)
were purchased from New England Nuclear (Boston, MA). TLC phospholipid
standards, PC, lyso-PC, phosphatidylethanolamine, phosphatidylserine, sphin-
gomyelin, fatty acid-free BSA, EGTA, aphidicolin, and RNase were from
Sigma Chemical Co. (St. Louis, MO). Deutero-PAF was obtained from Cas
cade Biochem, Ltd. (Berkshire. United Kingdom). TBDMSI reagent was from
Alltech Applied Science (Deerfield, IL). High performance TLC silica gel 60
plates were from E. Merck (Darmstadt, Germany). Organic solvents were
purchased from Carlo Erba (Milano, Italy). L659,989 was a generous gift from
Merck, Sharp & Dhome (Rahway, NJ). bPc-fos(human)-! cDNA probe was
obtained from ATCC (Rockville, MD).
Cell Culture. HEC-1A and SK-UT-1 cells were obtained from ATCC. The
HEC-1A in vitro cell line was established in 1968 by Kuramoto et al. (20) from
explants of adenocarcinoma of human endometrium. The cells were grown in
modified McCoy's 5A (Sigma) supplemented with 10% fetal calf serum
(GIBCO, Grand Island, NY), penicillin (100 units/ml), streptomycin (0.1
mg/ml), and 2.2 g/1 sodium bicarbonate as indicated by ATCC. Cultures were
carried out in a humidified atmosphere of 5% COi-95% air at 37Â°C.Mono-
layers were split every 4-5 days using trypsin (0.05% in Mg2*- and Ca2 +-free
PBS containing 0.02% EDTA), and the culture medium was renewed every
2â€”3days.
SK-UT-1 cells were isolated in 1972 from a human mixed uterine meso-
dermal tumor (leiomyosarcoma grade III). The cells were grown in Eagle's
minimal essential medium with 10% PCS as indicated from the ATCC. These
cells were used as control cells for [3H]thymidine incorporation and binding
studies.
PAF Synthesis ([3H]Acetate Incorporation into PAF). [3H]PAF synthe
sis was measured by quantitative incorporation of [3H]acetate into PAF as
described previously (21, 22). For these experiments, cells were grown to
confluence on 6-well plastic plates, washed twice in serum-free McCoy's 5A
medium containing 0.1% BSA, and preincubated in the same buffer in the
presence of 50 fiCi/well [3H]acetate. Stimuli were then added at the indicated
concentrations for the established times. The reaction was stopped by adding
3 ml of ice-cold chloroform:methanol:acctic acid (1:2:0.04, by volume), and
lipids were extracted twice in chloroform:mcthanol according to the Bligh and
Dyer extraction procedure (23). The lower (chloroform) phases, containing the
extracted lipids. were collected, washed once with methanohwater (10:9, v/v),
evaporated under nitrogen, and redissolved in 200 /il of chloroform:methanol
(9:1, v/v). Samples were then applied on heat-activated high performance TLC
silica gel 60 plates and developed in chloroform:methanol:water (65:35:6, by
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volume). The labeled phospholipid products were identified by cochromatog-
raphy with known standards. The K, value of PAF was 0.2. The lipid fractions
were visualized under an UV lamp after 2-p-toluidinylnaphthylene-6-sulfonate
exposure; areas corresponding to PAF were carefully scraped, and the radio
activity was counted by liquid scintillation. For [3H]PAF release experiments,
lipids were separately extracted, as described above, from the conditioned
medium and cell monolayers after the incubation procedure.
PAF acetyltransferase activity was assessed in lysates of HEC-IA cells by
measuring the incorporation of [3H]acetyl from radiolabeled acetyl-CoA into
[3H]PAF using lyso-PAF as substrate, as described previously (22, 24).
Identification of PAF-like Materials as Authentic PAF. We also per
formed gas chromatography-mass spectrometry analysis of PAF-like material
extracted from HEC-IA cells preincubated with A23187 for 15 min by using
a Perkin-Elmer 8420 gas chromatography-ion trap mass spectrometer (Perkin-
Elmer, Norwalk, CO), as recently described (22). The phospholipids, extracted
as described above, were reextracted from TLC powder, dried, and exposed to
phospholipase C (10 units/ml) hydrolysis by shaking for three h in 1 ml 0.5 M
Tris (pH 7.3) and 2.0 ml peroxide-free diethyl ether. The upper phase was
evaporated, and the residue was dissolved in 100 Â¿dof chloroform. One ml of
n-hexane was added, and the solution was applied to a small glass column
filled with 500 mg of silica gel, previously washed with 5 ml chloroform and
1 ml n-hexane. The sample was left at room temperature overnight in order to
allow acetyl migration from position 2 to 3 of l-O-radyl-2-acetyl glycerol (25).
It was then washed with 4 ml n-hexane, eluted with 4 ml chloroform, collected
in a reaction vial, and evaporated. The obtained diglyceride was then derivat-
ized by adding 100 fil of TBDMSI. The vial was capped and kept for 15 min
at 100Â°C;after cooling, 0.5 ml of chloroform were added, and the mixture was
washed with 2 ml of water. The lower phase was evaporated; then the residue
was redissolved in 20 /xl n-heptane and applied to the gas chromatograph-ion
trap mass spectrometer. Chromatographie separation was obtained using a
DB-1 (J&W, Rancho Cordova, CA) fused-silica capillary column (12 m x 0.25
mm internal diameter; 0.25-fi film thickness). The oven temperature was
programmed from 150Â°C(0.5-min hold) to 240Â°Cat 20Â°C/minand 5Â°C/minup
to 270Â°C.One 2-Â¡Ãºsample was injected in the splitless mode in a programmed
temperature vaporizer (250Â°C). Helium was used as the carrier gas at 10 psi
inlet pressure. Both full-scan mass spectra and SIM experiments were per
formed in the electron-impact mode at an ionizing energy of 70 eV. When
analysis was performed with SIM, the ion m/e 415 (M-57), which is produced
by cleavage of the (prr-butyl radical from the parent ion, was selected. Full-
scan spectra acquisition of internal standards were previously performed for
ion mass assignments.
For quantitative analysis of PAF, standard curves were prepared combining
PAF C:16 in the range 2-100 ng with 10 ng of deuterated internal standard and
subjecting them to the derivatization procedure described above.
Calcium Experiments. For intracellular calcium measurements, cells were
grown to confluence on plastic coverslips (Aclar; Allied Engineering Plastic,
Pottsville, PA). During the 24 h before the experiments, cells were maintained
in serum-free medium. [Ca2+ ]Â¡was determined using the calcium-sensitive dye
Fura-2/AM as described previously (26). HEC-IA cells were loaded with 1 yM
Fura-2/AM in the dark for 40 min at 37Â°Cin serum-free McCoy's 5A; then the
cells were washed and incubated for another 20 min in Fura-2-free medium.
Cells were then washed with Krebs-Henseleit HEPES-KHH propidium iodide-
free buffer (pH 7.4) containing 1.25 mM CaCl2> 5.36 min KC1, 0.81 MgSO4,
130.62 mM NaCl, 5.55 mM glucose, 8.60 mM HEPES sodium salt, and 11.7 mM
HEPES free acid. Coverslips were then mounted diagonally in a quartz cuvette
so that the excitation and emission paths were at a 45Â°angle to the coverslip.
The cuvette, containing 2 ml of KHH buffer, was maintained at 37Â°C.Fluo
rescence was measured using a spectrofluorometer (University of Pennsylva
nia Biomedicai Group, Philadelphia, PA) using a single-wavelength excitation
(340 nm)/emission (510 nm). Stimuli were added directly in the cuvette.
Calibration was performed using ionomycin (0.02 mM) to obtain Fmax, fol
lowed by EGTA (8 mM) to obtain Fmin. Fluorescence measurements were
converted to [Ca2+]Â¡according to Grynkiewicz et al. (27), assuming a Kd of
Fura 2 for calcium of 224 nM.
RNA Analysis. For Northern analysis, HEC1-A cells were incubated with
PAF, C-PAF, or L659,989 at the indicated concentrations and times in Mc
Coy's serum-free medium. Total cellular RNA was prepared by the hot-phenol
method (28) and quantitated by spectrofluorimetric analysis at 260 nm. Total
cellular RNA (20 /ig) was fractionated in a 1% agarose-formaldeyde gel and
then transferred overnight onto nylon membranes and baked at 80Â°Cunder
vacuum for 2 h. Membranes were prehybridized for l h and then hybridized
overnight at 65Â°Cwith a hybridization solution containing 10 mg/ml BSA, 7%
SDS, 0.25 M Church and Gilbert buffer, 1 mM EDTA (pH 8), and 0.2 mg/ml
hot-denatured sonicated herring sperm DNA. For RNA hybridization with the
cDNA probe, a 1.3-kilobase gel-purified Smal-HindUl cDNA fragment for
human c-fos protooncogene was used. The purified fragment was labeled with
deoxycytidine S'-la^PJtriphosphate by a nick translation kit (Promega, Mad
ison, WI), chromatographed by Nu-Clean D50 Disposable Spun Columns (IBI,
New Haven, CT), and denatured at 95Â°Cfor 10 min before use. After overnight
hybridization, the membranes were washed three times with 1% SDS, 0.2 M
Church and Gilbert buffer, and 0.1 mM EDTA (pH 8) at 65Â°Cfor 10 min. The
nylon membranes were submitted to autoradiography using Kodak X-Omat
AR film and Kodak X-Omatic regular intensifying screen at -80Â°C for 3 days.
Mitogenic Assay ([3H]Thymidine Incorporation). For this set of exper
iments, cells were plated in 24-well plastic plates at the initial density of
10,000 cells/well in complete culture medium. After 2 days of culture, cells
were maintained for 24 h in serum-free medium, and stimuli or vehicles (10 ^1)
were added at the indicated concentrations for the indicated times. All treat
ments were performed in triplicate. Cells were than incubated with [3H]thy-
midine (1 fiCi/well) during the last 4 h of stimulation. Cells were washed twice
with ice-cold 5% trichloroacetic acid and solubilized with 0.25 N NaOH in
0.1% SDS at 37Â°Cfor 20 min. Aliquots were transferred to plastic vials and
counted by liquid scintillation.
For experiments on the effect of L659,989 on cell number, cells were plated
at low density in 6-well plates, grown in complete culture medium, and treated
in triplicate for 5 days with L659.989 (10 (J.M)in the same medium. Cells were
trypsinized and counted with a Coulter Counter (Coulter Electronics, Ltd.,
Luton, United Kingdom).
Cell Cycle Analysis. HEC1-A cells (about 1.5 X IO6) were cultured in
100-mm tissue culture plates in 10 ml complete culture medium for 12-18 h;
then 5 ng/ml of aphidicolin was added. After 24 h, partially synchronized cells
were extensively washed in PBS, and 10 JU.Mof L659.898 were added in 10 ml
10% FCS/McCoy's medium and incubated for the indicated times. After
incubation, cells were washed twice with PBS, harvested using 3 ml trypsin/
EDTA (0.05/0.02%) in PBS, and centrifuged at low speed. Cells were resus-
pended at 1 X IO6 cells/ml in 2 ml of a fluorochrome solution containing 0.025
mg/ml propidium iodide, 0.025 mM EDTA, 0.015% Nonidet P-40, and 0.5 mg
RNase in PBS. Samples were incubated in the dark at room temperature for 30
min and stored at 4Â°Cuntil used for DNA analysis. Cell fluorescence was
measured in a FACScan flow cytometer (Becton Dickinson, Mountain View,
CA). The CELLFIT software was used to determine the distribution of cells in
the various cell cycle compartments as Gâ€ž/G,,S, and G2.
Binding Experiments. HEC-IA cells were grown to confluence in 24-well
plastic plates; 1.5 X IO5 cells were incubated in binding buffer (PBS contain
ing 3 mg/ml of free fatty acid BSA) at the indicated temperatures and for
varying times. Cells were incubated in the presence of increasing concentra
tions of [3H]PAF (0.6 nM-10 nM) without unlabeled ligands or fixed concen
tration (2 nM) of [3H]PAF with increasing concentrations (1-100,000 nM) of
unlabeled ligands. All of the measurements were obtained in triplicate. At the
end of the incubation periods, the supernatants were removed, and the cells
were washed six times in ice-cold Dulbecco-modified PBS containing 3 mg/ml
BSA. Cells were then solubilized in 200 Â¡uof 1% SDS containing 0.25 N
NaOH, and 190 Â¡Ãºof the total volume were counted in a beta counter.
Statistical Analysis. The binding data were evaluated quantitatively with
nonlinear least-squares curve-fitting using the computer program LIGAND.
The program provides objective measures of goodness-of-fit and objective
criteria for distinguishing between models of different complexity. The selec
tion of the best model was based on comparison of the weighted sum of
squares and/or the root mean square error. An F-test based on the "extra sum
of squares" principle was used (29). The computer program ALLFIT (30) was
used for the analysis of sigmoidal dose-response curves. This program uses the
constrained four-parameter logistic model to obtain estimates of ED50 and IC5U
values, the logit-log slope ("pseudo-Hill coefficient"), and relative potencies.
Results are expressed as mean Â± SEM. Statistical comparisons were
performed using unpaired Student's t test.
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RESULTS
PAF Synthesis by HEC-IA Cells. Preliminary experiments per
formed in HEC-IA cell sonicates showed the presence of lyso-PAP:
acetyl-CoA acetyltransferase activity in these cells. lyso-PAF:acetyl-CoA
acetyltransferase activity was time-dependent with a maximal activity at
15 min, followed by a plateau. PAF synthesis (measured as [3H]acetate
incorporation into PAF) was assessed in intact HEC-IA cells, both in
basal conditions and following stimulation with the calcium ionophore
A23187 (l /AM).[3H]Acetate incorporation into PAF in basal conditions
was 26,282 Â±2,302 cpm//Ag protein/60 min and was stimulated about
3-fold by a 1-h incubation with A23187 (84401 cpm//Ag protein/60 min;
n = 4). When lipids were separately extracted from cell pellets and
supernatant, 60.3 Â±10.4% (in unstimulated) and 71.05 Â±7.38% (in
A23187-stimulated cells) of [3H]PAF was found in the supernatant,
indicating that part of the newly synthesized PAF was released into the
medium by HEC-IA cells.
Identification of PAF Material Derived from HEC-IA Cells as
Authentic PAF. Gas chromatography-mass spectrometry analysis of
phospholipase C-treated and TBDMSI-derivatized PAF-like material
comigrating with authentic PAF isolated from A23187-stimulated
HEC-IA cells showed the presence of a Chromatographie peak with
identical retention time of deuterated standard PAF C16:0. Fig. 1 illus-
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Fig. 1. Electron-impact mass spectra of the TBDMSI derivatives produced from
HEC-lA-derived PAF-like material (A) and authentic PAF (ÃŸ).The peak at m/z 415
represents the [M-57] ion for C16:0 ether.
trates the full mass spectrum of TBDMSI derivatives of PAF extracted
from HEC-IA cells (Fig. L4) as well as for authentic PAF C16:0 (Fig.
15). When monitored by SIM, the ion m/z 415 (M-57) of the material
extracted from HEC-IA cells showed the same retention time as the PAF
standard (not shown). These results indicate that l-O-alkyl-sn-2-acetyl-
glycerophosphocholine, the biologically active PAF, represents the pre
dominant PAF species because the acyl-PAF analogue (l-O-acyl-in-2-
acetyl-glycerophosphocholine) has a different electron-impact mass
spectrum and a different gas Chromatographie retention time in our
system. For quantitation of PAF, 16:0 deuterated-PAF was added to total
HEC-IA lipids as internal standard, and after several purification proce
dures, the TBDMSl-derivatives were analyzed. The amount of 16:0 PAF
in HEC-IA cells was estimated to be approximately 40 ng PAF/17.4 mg
DNA/15 min incubation.
Effect of PAF on [Ca2+], in HEC-IA Cells. PAF induced a
dose-dependent increase of [Ca2+]Â¡in Fura 2-loaded HEC-IA cells
(Fig. 3/4) with an apparent EC50 of 5.6 Â±0.7 nM (n â€”4) and a
maximal effect of 181 Â±12% increase over basal value. The increase
of [Ca2+]Â¡appears to be mediated by specific PAF receptors, as the
preincubation (2 min) with the PAF receptor antagonist L659,989
dose-dependently abolished the effect of 10 nM PAF (Fig. 2B) with an
IC50 of 19 Â±1 nM (n = 3). The calcium increase in response to PAF
(10 nM) was still present in the absence of extracellular calcium
([Ca2+]e, 0 + 4 mM EGTA), whereas it was completely abolished in
cells simultaneously loaded with both Fura 2/AM and the intracellular
calcium chelator BAPTA (Fig. 3/4, inset). These findings suggest that
the initial peak triggered by PAF is the result of a release of calcium
from intracellular stores, whereas the sustained phase likely represents
an influx of calcium from the extracellular medium.
Effect of PAF on c-fos mRNA Steady-State Levels. The effects
of PAF (0.1 UM) and its stable analogue C-PAF (0.1 /AM)on c-fos
mRNA expression were assessed over a 2-h treatment period. The two
phospholipids caused a significant increase in c-fos mRNA steady-
state transcript levels (Fig. 3) at 15-, 30-, and 60-min treatments with
a maximal increase in density of 22-fold at 30 min with PAF and of
28-fold at 60 min with C-PAF. The effect of PAF on c-fos gene
expression was dose dependent (Fig. 4/4) with an EC5()of 0.13 /AMand
a maximal response (13-fold increase) at the concentration of 10 UM.
Coincubation with equimolar concentrations of the PAF antagonist
L659,989 completely abolished the effect of 0.1 /AMPAF on c-fos
mRNA steady-state transcript levels (Fig. 4B), suggesting the involve
ment of specific PAF receptors.
Effect of PAF and the PAF Receptor Antagonist L659,989 on
Proliferation of HEC-IA Cells. Mitogenic assays of HEC-IA cells
demonstrated a substantial increase of [3H]thymidine incorporation in
PAF-stimulated cells after 24 h incubation. Such increase was dose
dependent with an EC50 of 0.7 Â±0.2 /AM(n = 5) and a maximal effect
of 3.92 Â±0.89-fold increase over the basal state (n = 5). The effects
of the two PAF precursors, lyso-PAF and lyso-PC, on DNA synthesis
were also studied. We found that both lysophospholipids were able to
stimulate [3H]thymidine uptake, although with lower potency than
PAF. The EC5U for the 1-O-alkyl-PAF precursor lyso-PAF was
1.56 Â±0.2 JAM(n = 3), whereas the EC50 for the 1-O-acyl-PAF
precursor lyso-PC was 12.5 /AM(n = 2). Conversely, treatment of the
cells with the PAF receptor antagonist L659,989 dramatically de
creased [3H]thymidine uptake. Such effect was already present after
16-18 h of treatment and peaked around 48 h (data not shown). The
effect of L659,989 was dose dependent with an IC50 of 2.17 Â±0.7 JAM
(n = 6) and a maximal inhibiting effect of about 90% obtained with
32 /AM.Both the proliferative effect of PAF and the antiproliferative
effect of L659.989 were completely antagonized by concomitant
incubation with equimolar concentrations of the two agents. Fig. 5
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[3H]thymidine incorporation studies in SK-UT-1 cells after incu
bation (24-48 h) with PAF (0.1-10 /AM)and its antagonist L659,989
(0.1-10 JXM)did not show any modification of basal uptake with either
agonist at any concentration tested (n = 2; data not shown).
Cell Cycle Analysis. To study the effect of L659,989 on the cell
cycle, HEC-IA cells were synchronized by a 24-h exposure to 5
/Â¿g/mlaphidicolin, a potent nonspecific inhibitor of DNA polymerase
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Fig. 2. Dose-response curve of PAF-mediated [Ca2 ' ]Â¡increase in Fura-2 loaded
HEC-IA cells (A). The EC5C,for PAF was 5.6 Â±0.7 nM (n = 4). Inset, representative
tracings of PAF (10 nM)-stimulated Ca2+ increase in the presence and in the absence of
extracellular calcium and in BAPTA-loaded cells. B. dose-response curve of inhibition of
PAF ( 10 nM)-mediated Ca- ' increase after 2 min preincubation with the PAF antagonist
L659.989. The IC5U for this curve was 19 Â±1 nM (n = 3). Bars, SEM.
Fig. 3. Time course of PAF (Ãœ.1 Â¿iM)-mediatedand C-PAF (0.1 ^.M)-mediated increase
of c-fos mRNA steady-state transcript levels in HEC-IA cells. Ethidium bromide staining
of total RNA loaded in each lane is shown below Northern blot.
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shows the result of a typical experiment on the effect of PAF and
related compounds on DNA synthesis.
We also evaluated the effect of L659,989 on cell number by
counting cells with a Coulter counter during 5 days of treatment. As
shown in Fig. 6, these experiments confirmed cell growth inhibition
by treatment with 10 JLIML659,989, starting from the first day of
treatment. In addition, removing the PAF antagonist from the cells
after 1 day of treatment by extensive washing with PBS and subse
quent addition of complete medium (10% PCS) restored the cell
number to the control value within 24 h, indicating a complete
restoration of cell proliferation (not shown).
To study whether the antiproliferative effect of L659,989 on
HEC-IA cells was due to a cytotoxic action, we evaluated the effect
of 10 (AML659,989 on cellular lÃ¡clate dehydrogenase activity (as
sessed by an automatized colorimetrie method) following 24 h of
treatment. LÃ¡clatedehydrogenase cell contenÃ-was noi changed by the
treatmenl wilh L659,989 (3854 Â± 140.2 internalional units/well in
conlrols versus 3813 Â± 31.5 inlernalional units/well in treated
samples; n = 3).
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Fig. 4. A, dose-response curve of PAF-mediated increase of c-fos expression. B, effect
of the PAF receptor antagonist L659.989 on PAF-induced increase of c-fos steady-state
transcript levels. In both experiments, HEC-IA cells were incubated with the different
agonists for 30 min. Ethidium bromide staining of total RNA loaded in each lane is shown
below each Northern blot.
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a (31). After such treatment, about 70% of the cells were in GI(/G,-
early S, as indicated by fluorescence emission of propidium iodide-
stained nuclei of the cells (not shown). Removal of aphidicolin (by
extensive washing) allowed the cells to progress through the cell
cycle. After a 4-h release from the aphidicolin block, the majority of
the cells entered S, while 8 h later, most of the cells traversed G2-M.
Eighteen h after aphidicolin release, the synchronized cells returned to
0,,-G, and started to traverse S again. L659,989 treatment (10 /AM)did
not affect the cell cycle profile in the first 12 h. After 18 h, L659,989
caused a partial accumulation of the cells in the G2-M phase (Table 1).
Thirty-six h after release from aphidicolin block, the PAF antagonist
caused an accumulation into G()-G, and a 50% reduction of S cells
Table 1 Effect of the PAF receptor antagonist L659.9M (10 UMÃ•on cell cycle
distribution of partially synchronized HEC-IA cell al IK and 36 h after release from
aphidicolin block
H after
aphidicolin
release18
Control
L659.989GÃŒ44.58
Â±3.55
35.78 Â±1.52S11.
54 Â±0.35
10.81 Â±0.24G2/M44.13
Â±3.67
53.69 Â±1.6ft
36
Control
1.659,989
49.92 Â±3.29
57.32 Â±1.14
26.40 Â±0.35
16.65 Â±2.10"
" P < 0.05 versus control; Â«= 3 experiments.
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Fig. 5. Effect of 24-h treatment with increasing concentrations of PAF. lyso-PAF.
L659.989. and the combination of equimolar concentrations of PAF plus L659.989 on['H]lhymidine uptake in HEC-IA. Results of a typical experiment (of at least three similar
experiments performed in triplicate) are shown.
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Fig. 6. Effect of the PAF antagonist L659.9S9(10 JÂ¿M)on HEC-IA cell number during
5 days of continuous treatment. Results are mean of triplicates of a representative
experiment (of three similar experiments); har\. SEM. Cells were plated at the initial
concentration of 50.(XM)cells/well.
over control values (P < 0.05; Table 1). Fig. 7 shows the result of a
typical experiment.
Binding Studies. The binding reaction of [3H|PAF to HEC-IA
cells was dependent on time and temperature. In contrast, the cell line
SK-UT-1 did not bind ['HJPAF (data not shown). Specific ['HjPAF
binding to HEC-IA cells was increasing as a function of time at 4, 22,
and 37Â°C,reaching a maximum after 45 min at 37Â°C,90 min at 22Â°C,
and 24 h at 4Â°C(data not shown). Since the binding at 4Â°Cwas much
more stable than in other experimental conditions, experiments were
carried out at 4Â°Cfor 24 h.
Fig. 8/\ shows a typical family of competition curves among PAF, the
PAF antagonist L659,989, and the PAF precursor lyso-PAF performed in
HEC-1A cells. Using a subnanomolar (0.2 nM)concentration of the tracer
to facilitate analysis of the high affinity portion of the curves, we obtained
evidence for heterogeneity of the binding sites. Indeed, PAF and
L659,989 competed for [^HJPAF binding in either nanomolar or micro-
molar concentrations, while the PAF precursor lyso-PAF displaced
[3H]PAF only in the micromolar range. To further test the hypothesis that
a heterogeneity of sites for PAF and L.659,989 is present in HEC-IA
cells, we generated multiple families of competition curves. Simultaneous
computer analysis using the LIGAND program (29) was performed for
12 curves for a total number of 342 experimental determinations. Quan
titative analysis indicated that a model involving only one site was
severely inadequate. Introduction of a second independent class of sites
significantly and dramatically improved the goodness-of-fit (P <5C
0.0001). Fig. 8, B and C, graphically shows the result of simultaneous
modeling. The first site (R,) is a low capacity site (ÃŸmax= 269 Â±183
fmol/10" cells) that binds with nanomolar affinity PAF (Kd = 1.7 Â±1.6
nM) and L659,989 (A"d= 0.4 Â±0.4 nM). The second site (R2) is a high
capacity site (ÃŸmax= 3.71 Â±0.63 nmol/10'' cells) that binds with
micromolar affinity PAF (Kd = 9.7 Â± 1.45 JAM) and L659.989
(Kj = 10.6 Â±2 JAM).
When heterologous competition curves using lyso-PAF were in
cluded in receptor modeling, we found evidence for interactions of
lyso-PAF only with the low affinity site, R2 (KÂ¿= 4.8 Â± 1 JAM;
n = 4). Concerning R2, similar binding parameters were also obtained
incubating HEC-IA cells in the presence of [3H]PAF and competitors
at 22Â°Cfor 90 min. Since at this time and temperature PAF, L.659,989
and lyso-PAF do not affect cell growth (data not shown), it is unlikely
that binding parameters to R2 could be affected by parallel changes in
cell proliferation.
The statistical hypothesis that experimental data obtained in DNA
synthesis or binding studies to R2 using L.659,989 share common
IC50s was tested by first forcing the curves to share this parameter and
then by verifying that such constraint has minimal effect on several
indicators of the goodness-of-fit, including the F ratio test (30). Since
the F test was not significantly different from unity, it was derived that
the shared parameter is compatible with each other (P = 0.53; mean
IC51I,7.5 Â±2.5 /J.M).
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Fig. 7. Flow cytometric analysis of cell cycle dis
tribution of synchronized HEC-1A cells 18 and 36 h
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ond row). Representative tracings of three similar
experiments.
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DISCUSSION
This study strongly indicates that PAF supports an autocrine pro-
liferative loop in the human endometrial cancer cell line HEC-IA.
Indeed, we have shown that HEC-IA cells are both actively synthe
sizing and responsive to PAF in terms of [Ca2+]Â¡,DNA synthesis, and
expression of the protooncogene c-fos. In addition, the third genera
tion PAF receptor antagonist L659.989 dramatically inhibits HEC-IA
cell proliferation, further supporting the presence of an autocrine
proliferative circuit. On the contrary, PAF or its antagonist L659,989
did not elicit any effect on thymidine uptake in the uterine leiomyo-
sarcoma cell line SK-UT-1. Binding studies indicate that the biolog
ical effects of PAF and L659,989 are mediated by specific receptors
present in HEC-IA cells and absent in SK-UT-1 cells.
Production of PAF by HEC-IA cells occurs at least through the
anabolic, remodeling pathway of PAF synthesis, as demonstrated by
the high [3H]acetate incorporation into PAF both in basal conditions
and following stimulation with the ionophore A23187. We have also
shown that about 60% of newly synthesized [3H]PAF is released into
the cell-conditioned medium, suggesting the possibility of an auto
crine action of this phospholipid. Moreover, gas chromatography-
mass spectrometry analysis revealed that the large majority of PAF
synthesized by HEC-IA cells consists of the biologically active PAF
species 1-O-alky l-sn-glycero-3-phosphocholine.
Addition of PAF to HEC-IA cells resulted in a rapid, dose-depen
dent and byphasic increase in [Ca2+]Â¡.Such increase appears to be
mediated by specific PAF receptors because it is inhibited by the PAF
antagonist L659,989 and seems to involve both release of Ca2+ from
intracellular stores as well as influx from extracellular medium. Fur
thermore, incubation with PAF resulted in a dose- and time-dependent
increase of expression of the c-fos protooncogene. Induction of c-fos
mRNA expression was inhibited by the PAF antagonist L659,989,
again suggesting the involvement of a specific receptor. These results
are in agreement with several other studies demonstrating an effect of
PAF on immediate-early gene expression (12-16). However, an effect
of PAF on spontaneous cell proliferation has been reported only for
Raji lymphoblasts, a Burkitt lymphoma-derived B-cell line (32), and
guinea pig bone marrow cells (33). Moreover, the antiproliferative
effect of some PAF receptor antagonists does not appear to be related
to PAF receptors (18, 19). Therefore, we next investigated the effect
of PAF and its receptor antagonist L659,989 on cell proliferation in
order to demonstrate a mitogenic effect of this phospholipid in
HEC-IA cells. We now report that PAF stimulates [3H]thymidine
incorporation in the HEC-IA cell line. Such stimulation was dose
dependent and appears to be mediated by a PAF receptor, as demon
strated by the inhibition of this effect by equimolar concentrations of
the antagonist L659,989. In addition, L659,989 strongly inhibited
[3H]thymidine uptake by these cells, and this effect was prevented by
concomitant incubation with equimolar concentrations of PAF. These
results strongly indicate, for the first time, the presence of a PAF-
mediated autocrine loop, which appears to be critical for the progres
sion of HEC-IA cells throughout the cell cycle. In fact, the antipro
liferative effect of the PAF antagonist L659,989, assessed by studies
on thymidine uptake and cell number, appears to be mediated by a
relative accumulation of cells in G2-M.
The different biological effects of PAF in HEC-IA cells ([Ca2+]Â¡
increase, early oncogene expression, and DNA synthesis) have been
obtained at different concentrations of the agonist, suggesting that
calcium increase might be upstream to oncogene expression and DNA
synthesis. On the other hand, PAF-mediated calcium signaling and
mitogenesis in HEC-IA cells could be mediated by distinct subtypes
of receptors. Indeed, we found the presence of two distinct classes of
binding sites for [3H]PAF in HEC-IA cells. The first site, R,, binds
PAF and L659,989 in nanomolar concentrations, while the second
one, R2, shows affinity in the micromolar range. The PAF precursor
lyso-PAF apparently interacts only with the low affinity site, R2. The
presence of high and low affinity binding sites for PAF has been
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Fig. 8. Competition curves for PAF binding to HEC-1A cells. Ordinale, BAT;ahscissa,
total ligand concentration (labeled and unlabcled) on log scale. A. results obtained in a
typical experiment using PAF (O), lyso-PAF ( 0 ), and L659.989 (â€¢)as competitors. B
and C, results from 12 experiments analyzed simultaneously using a two-site model (29).
Each point is the mean of triplicate determination.
reported previously in the pregnant rabbit uterus (7). Although is
difficult to stress which binding sites mediate the different biological
effect of PAF, the effect of L659,989 on inhibition of DNA synthesis
could be explained by binding to the low affinity site R2. Hence,
mitogenic effects could be dissociated from calcium fluxes, as re
cently reported for fibroblast growth factor receptors (34), suggesting
interactions with other signaling pathways such as tyrosine kinase
activation (34). PAF has been recently shown to increase tyrosine
kinase activity both in platelets (19) and in proliferating cells (11, 12).
In the A-431 epidermoid carcinoma cell line, PAF stimulation of c-fos
expression involves both tyrosine kinase and PKC activation (12),
although these effects appear to be dissociated from phospholipase C
stimulation. Moreover, activation of tyrosine kinase seems to precede
PKC activation (12). Preliminary data obtained in our laboratory also
suggest a possible involvement of tyrosine kinase activation in the
proliferative mechanism of PAF in HEC-IA cells.4
Interestingly, in HEC-IA cells as in rabbit endometrium, specific PAF
binding was displaced by the PAF precursor lyso-PAF (7-9). Such
finding might explain the increase of thymidine uptake detected in
lyso-PAF-stimulated and, to a lesser extent, lyso-PC-stimulated HEC-IA
cells. Indeed, although lyso-PAF is thought to be biologically inactive, a
specific action in endometrial cells through PAF receptors is suggested
(7, 8). It must be also stressed that lyso-PAF and other lysophospholipids
have been reported to stimulate PKC activity directly (35); thus, a
proliferative action on HEC-IA cells through PKC activation cannot be
excluded. An alternative explanation is given by the high intrinsic capac
ity of HEC-IA cells to produce PAF. Indeed, lyso-PAF might be metab
olized by the cells to generate PAF which, in turn, stimulates cell
proliferation and inhibits [3H]PAF binding.
In conclusion, we have shown evidence for the presence of an
autocrine proliferative loop exerted by PAF in the human endometrial
adenocarcinoma cell line HEC-IA. Additional studies will be neces
sary to establish a clinical implication of our finding.
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